The clinical performance is complex and often involves multi-system complications. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HL-associated HBV. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.